Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Defibrotide - Jazz Pharmaceuticals

Next Previous
Drug Profile

Defibrotide - Jazz Pharmaceuticals

Alternative Names: Defibrotide sodium; Defitelio; Fraction P; JZP-381; Noravid; NS 73; Prociclide

Latest Information Update: 21 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gentium
  • Developer Fukushima Medical University; Gentium; Jazz Pharmaceuticals plc; Nippon Shinyaku; Swedish Orphan Biovitrum; University of California at San Francisco
  • Class Antithrombotics; Nucleotide aptamers; Polydeoxyribonucleotides
  • Mechanism of Action Angiogenesis inhibitors; Heparanase inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Veno-occlusive disorders; Thrombotic thrombocytopenic purpura; Graft-versus-host disease
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Veno-occlusive disorders
  • Phase II Graft-versus-host disease; Neurological disorders; Thrombotic microangiopathies
  • Market Withdrawal Deep vein thrombosis; Thrombosis
  • No development reported Diabetic nephropathies; Multiple myeloma

Most Recent Events

  • 21 Nov 2025 Launched for Veno-occlusive disorders (In adolescents, In children, In adults, In infants) in Switzerland (IV), prior to November 2025 (Jazz Pharmaceuticals website, November 2025)
  • 21 Nov 2025 Launched for Veno-occlusive disorders (In adolescents, In children, In infants, In adults) in Iceland (IV), prior to November 2025 (Jazz Pharmaceuticals website, November 2025)
  • 21 Nov 2025 Launched for Veno-occlusive disorders (In adults, In infants, In children, In adolescents) in Liechtenstein (IV), prior to November 2025 (Jazz Pharmaceuticals website, November 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top